What's new for injection drug users with HIV infection?

Sexually Transmitted Infections

Volumn 79, Issue 2, 2003, Pages 80-83

  Clarke, Susan M ^a   Mulcahy, F M ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; RITONAVIR;

ASIA; CHINA; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG METABOLISM; EDITORIAL; EPIDEMIC; HEALTH CARE ACCESS; HEALTH PROGRAM; HEPATITIS C VIRUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MEDICAL RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; STANDARD; TIME; VIET NAM; VIRUS INFECTION; WITHDRAWAL SYNDROME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE OUTBREAKS; DRUG INTERACTIONS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HUMANS; METHADONE; NARCOTICS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0037395190     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.79.2.80     Document Type: Editorial

References (43)

1. UNAIDS/WHO. AIDS epidemic update. December 2001.
2. Ling S, Graf M, Zhang Y, et al. Characterization of a virtually full-length HIV type-1 genome of a prevalent intersubtype (C/B′) recombinant strain in China. J Virol 2000;74:11367-76.
3. Lai S, Liu W, Chen J, Yang J, et al. Changes in HIV-1 incidence in heroin users in Guangxi province, China. J AIDS 2001;26:365-70.
4. Hien NT, Giang LT, Binh PN, et al. Risk factors of HIV infection and needle sharing among injecting drug users in Ho Chi Minh City, Vietnam. J Subst Abuse 2001;13:45-58.
5. Bobkov A, Kazennova E, Khanina T, et al. An HIV type-1 subtype strain of low genetic diversity continues to spread among injecting drug users in Russia: study of the new local outbreaks in Moscow and Irkutsk. AIDS Res Hum Retrovir 2001;17:257-61.
6. Pandrea I, Descamps D, Collin G, et al. HIV type-1 genetic diversity and genotypic drug susceptibility in the republic of Moldova. AIDS Res Hum Retrovir 2001;13:1297-304.
7. Saraswathy TS, Ng KP, Sinniah M. HIV type-1 subtypes among Malaysian intravenous drug users. Southeast Asian J Trop Med Public Health 2000;2:283-6.
8. Panda S, Chatterjee A, Bhattacharya SK, et al. Transmission of HIV from injecting drug users to their wives in India. Int J STD AIDS 2000;7:468-73.
9. Rhodes T, Ball A, Stimson GV, et al. HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction 1999;94:1323-36.
10. Van Ameijden EJC, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998;12:625-33.
11. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough:lessons from the Vancouver injecting drug use study. AIDS 1997;11:F59-65.
12. Clarke S, Keenan E, Bergin C, et al. The changing epidemiology of HIV infection in injecting drug users in Dublin, Ireland. HIV Med 2001;2:236-40.
13. Strathdee SA, van Ameijden EJC, Mesquita F, et al. Can HIV epidemics among injecting drug users be prevented? AIDS 1998;12:S71-9.
14. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995;274:1226-31.
15. Des Jarlais DC, Friedman S, Sotheran JL, et al. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA 1994;2:121-7.
16. Des Jarlais D, Marmor M, Friedman P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health 2000;90:352-9.
17. Sabbatini A, Carulli B, Villa M, et al. Recent trends in the HIV epidemic among injecting drug users in Northern Italy, 1993-1999. AIDS 2001;16:2181-5.
18. Carpenter CC, Cooper DA, Fischyl MA, et al. Antiretroviral therapy in adults:updated recommendations of the International AIDS Society USA panel. JAMA 2000;283:381-90.
19. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998;338:853-60.
20. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280:544-6.
21. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. J Epidemiol Commun Health 1999;53:4-8.
22. Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med 2003;4:33-7.
23. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ 2001;165:405-10.
24. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001;15:423-4.
25. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of HAART. AIDS 2001;15:1115-23.
26. Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV. The AIDS Reader 2002;12:305-7, 312-16.
27. Stenzel MS, McKenzie M, Adelson J, et al. Enhancing Adherence to HAART: Modified directly observed therapy. The AIDS Reader 2001;6:317-28.
28. Fischl M, Rodriguez A, Scerpella E, et al. Impact of directly observed therapy on outcomes in HIV clinical trials. Abstract 71:7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Jan 2000.
29. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J AIDS 2001;28:47-58.
30. Patrick D, Tyndall MW, Cornelisse PGA, et al. Incidence of hepatitis C virus among drug users during an outbreak of HIV infection. CMAJ 2001;165:889-95.
31. Lauer GM, Walker B. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
32. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha2b and ribavarin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;16:2149-55.
33. Nasti G, Di Gennaro G, Tavio M, et al. chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alpha-2b and tribavirin. AIDS 2001;15:1783-7.
34. Kewn S, Hoggard PG, Henry-Mowatt JS, et al. Intracellular activation of 2′,3′-dideoxyinosine and drug interactions in vitro. AIDS Res Hum Retrovir 1999;15:793-802.
35. Des Jarlais D, Schuchat A. Hepatitis C among drug users: déjà vu all over again? Am J Public Health 2001;91:21-2.
36. Tillmann HL, Heiken H, Knapik-Botor A, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001;345:715-24.
37. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-8.
38. Dyer KR, Foster DJR, White JM, et al. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients:comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999;65:685-94.
39. Clarke S, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharm 2001;3:213-7.
40. Clarke S, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for the use of nevirapine to treat injecting drug users. Clin Infect Dis 2001;33:1595-7.
41. Clarke S, Mulcahy F, Bergin C, et al. The pharmacokinetic interaction between methadone and nelfinavir. Abstract 276, 5th International Congress on Drug Therapy in HIV infection. Glasgow, Oct 2000.
42. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir/ritonavir. Clin Infect Dis 2002;34:1143-5.
43. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG 401). J AIDS 2001;27:153-60.